Groupement Hospitalier Edouard Herriot
Lyon, 69437, France
NCT Number: NCT04983654
Sickle Cell Disease is the most frequent genetic disease in the world (representing one birth over 1900, in France). The polymerization of the abnormal hemoglobin (i.e., HbS) when deoxygenated is at the origin of a mechanical distortion of red blood cells (RBC) into a crescent-like shape. Sickled RBCs are very fragile and rigid, which lead patients to have severe anemia and to develop frequent and repeated painful vaso-occlusive crises. Furthermore, the repetition of sickling-unsickling cycles causes irreversible damages to the RBCs, which shorten their half-life. Accumulation of free hemoglobin and heme in the plasma is involved in blood vessels lesions in both the macro- and micro- circulation.
The resulting vascular dysfunction could explain why limb ulcers are 10 fold more frequent in patients with sickle cell disease compared to the general population and may happen at a younger age. Limb ulcers induce significant morbidity (delay of healing between 9 and 26 weeks in the french cohort), and are associated to significant pain (needing opioid pain-killer) and increase the risk of infection. Cost of care is also increased. Moreover, ulcers induce missed school and work days.
Data on cutaneous microcirculation and ulcers physiopathology in patients with sickle cell disease are scarce. We want to realise a microcirculatory and neurological functional study of patients with with and without ulcers and a characterization of biomarkers present in the blood or in the wound fluid which can participate to ulcers physiopathology.
To ensure healing, adapted therapeutics are essential. Several strategies are proposed such as: lifestyle measures (venous compression, lower limb elevation, rest), dressings, hyperbaric oxygenotherapy (also used in diabetic ulcers). The project is devoted to study the mechanisms involved in leg ulcers and the effects of therapeutical/behavioral strategies.
Looking for future studies?
Notify Me18 year–130 year
All sexes
Interventional
Not applicable
Lyon, 69437, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
For patients with limb ulcers : at inclusion visit and after healing or at 6 months if ulcer does not heal:
For patients without limb ulcers : at inclusion visit only
Time frame: Day 1
Cutaneous microvascular function is assessed with :
Time frame: Day 1
Analysis of hemorheological characteristics in the 2 arms after blood test with blood viscosity and RBC rheological measurements (deformability/aggregation)
Time frame: Day 1
Analysis of metalloproteases (MMP-8 and MMP-9) and inflammatory markers (TNF-alpha, Il-6, Il1-beta, VCAM 1, P-selectin) in the wound fluid
Time frame: At initial visit
Analysis of inflammatory markers in the blood and comparison between the 2 arms
Time frame: through study completion, an average of 6 months
Delay of granulation tissue appearance, delay of healing according treatment used
Time frame: through study completion, an average of 6 months
Compare results (previously described) in the group of patients with ulcers, between initial and second visit
Hospices Civils de Lyon
Other
Acronym: DrepanO2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06742983
Pathologic Processes, Pathological Conditions, Signs and Symptoms
Ismailia, Egypt
View Trial DetailsNCT06873867
Full Thickness Skin Defects, Pathologic Processes
Mandya, Karnataka, India
View Trial DetailsNCT00450216
Arthritis, Arthritis, Rheumatoid
View Trial DetailsNCT06464250
Cardiovascular Diseases, Diabetes Complications
Istanbul, Turkey (Türkiye)
View Trial Details